Form 4: Catalyst Pharmaceuticals Director Acquires Shares Through Vesting of Restricted Stock Units

Director Tamar Thompson acquired 1,413 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• Tamar Thompson, a director at Catalyst Pharmaceuticals, acquired 1,413 shares of common stock on December 9, 2024.
• The acquisition resulted from the vesting of restricted stock units.
• These restricted stock units vest in three equal tranches, with the first tranche vesting on December 8, 2024.
• The shares were delivered to the reporting person on December 9, 2024.
• Following the transaction, Ms. Thompson directly owns 1,413 shares of Catalyst Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The vesting of restricted stock units indicates a long-term commitment by the director.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to the vesting of equity compensation for a company director, which is a common practice in publicly traded companies.

Comparison to Industry Standards

• The vesting schedule of the restricted stock units, with equal tranches over three years, is a typical vesting schedule for director equity compensation.
• Many companies use restricted stock units as a form of long-term incentive for directors and executives.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with the company's long-term performance.

Key Dates

Keywords

Catalyst Pharmaceuticals, Director, Tamar Thompson, Stock Acquisition, Restricted Stock Units, Vesting, Share Ownership